No Evidence of Hepatitis C Virus Infection in Individuals with Cardiovascular Disease in Mashhad
Archives of Medical Laboratory Sciences,
Vol. 7 (2021),
13 March 2021
,
Page 1-5 (e13)
https://doi.org/10.22037/amls.v7.33445
Abstract
Background and Aim: Hepatitis C virus (HCV) infection is one of the leading causes of morbidity and mortality worldwide. It has been hypothesized that a number of bacteria and viruses might be involved in the pathogenesis of cardiovascular disease. The aim of this study was to define the prevalence of HCV in patients with cardiovascular disease in comparison with a control group.
Methods: In this study, 281 individuals including 143 cardiovascular patients and 138 healthy controls were assessed for identification of HCV antibodies. The data collection was done between April 2016 and February 2017. The prevalence of HCV antibodies was determined by the enzyme-linked immunosorbent assay (ELISA) method.
Results: There was no HCV infection in both patients with or without cardiovascular disease. There was a significant direct correlation between cardiovascular diseases and mean level of FPG (Fasting plasma glucose) (p<0.001). Also the Systolic and Diastolic blood pressures were significantly higher in the patients with cardiovascular disease (p<0.001 and p=0.005, respectively).
Conclusion: The results of this study show that no evidence of HCV infection is found among a group of cardiovascular patients in the city of Mashhad.
*Corresponding Author: Zahra Meshkat; Email: meshkatz@mums.ac.ir
Please cite this article as: Shakeri Hoseinabad M, Aryan E, Ghayour Mobarhan M, Moohebati M, Abolbashari S, Gholoobi A, Houshyar Chechaklou A, Yaghoubi A, Meshkat M, Meshkat Z. No Evidence of Hepatitis C Virus Infection in Individuals with Cardiovascular Disease in Mashhad. Arch Med Lab Sci. 2021;7:1-5 (e13). https://doi.org/10.22037/amls.v7.33445
- Hepatitis C Virus
- Cardiovascular Disease
- Prevalence
- Iran
- Mashhad
How to Cite
References
Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A, et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation. 2014;129(14):1493-501.
Campbell LA, Rosenfeld ME. Infection and Atherosclerosis Development. Archives of medical research. 2015;46(5):339-50.
Patterson B, Rausch DA, Irwin DE, Liang M, Yan S, Yawn B. Risk of myocardial infarction and composite vascular events in patients with herpes zoster: 2007-2014 united states claims data analysis. Journal of the American College of Cardiology. 2018 Mar 10;71(11S):A177.
Ivey KS, Edwards KM, Talbot HK. Respiratory Syncytial Virus and Associations With Cardiovascular Disease in Adults. J Am Coll Cardiol. 2018;71(14):1574-83.
Onoue K, Saito Y. Hepatitis C Virus and Cardiovascular Disease. Circulation Journal. 2018;82(6):1503-4.
Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med. 2010;362(13):1248-9.
Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR, Jr., Sacco RL, et al. Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation. 2005;111(5):576-82.
Hujoel PP, Drangsholt M, Spiekerman C, DeRouen TA. Pre-existing cardiovascular disease and periodontitis: a follow-up study. Journal of dental research. 2002;81(3):186-91.
Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, et al. Fields virology, Lippincott Williams & Wilkins. Philadelphia, PA [Google Scholar]. 2007.
Alter MJ. Epidemiology of hepatitis C in the West. Seminars in liver disease. 1995;15(1):5-14.
Pfaender S, Brown RJ, Pietschmann T, Steinmann E. Natural reservoirs for homologs of hepatitis C virus. Emerg Microbes Infect. 2014;3(3):e21-e.
World Health O. Global hepatitis report 2017. Geneva: World Health Organization; 2017 2017.
Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-14.
Clément S, Pascarella S, Negro F. Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance and oxidative stress. Viruses. 2009;1(2):126-43.
Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut. 2005;54(7):1003-8.
Negro F, Clément S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. Journal of viral hepatitis. 2009;16(10):681-8.
Alter MJ. Prevention of spread of hepatitis C. Hepatology. 2002;36(5 Suppl 1):S93-8.
Taherkhani R, Farshadpour F. Epidemiology of hepatitis C virus in Iran. World journal of gastroenterology. 2015;21(38):10790-810.
Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology. 2002;36(5 Suppl 1):S99-105.
Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436-41.
Group GBOHCW. Global burden of disease (GBD) for hepatitis C. Journal of clinical pharmacology. 2004;44(1):20-9.
Hahné SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13:181.
Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. American journal of epidemiology. 2007;166(2):196-203.
Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. International journal of medical sciences. 2006;3(2):47-52.
Martins T, Narciso-Schiavon JL, Schiavon Lde L. [Epidemiology of hepatitis C virus infection]. Revista da Associacao Medica Brasileira (1992). 2011;57(1):107-12.
Rotman Y, Liang TJ. Coinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical Outcomes. Journal of Virology. 2009;83(15):7366.
Guiltinan AM, Kaidarova Z, Custer B, Orland J, Strollo A, Cyrus S, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. American journal of epidemiology. 2008;167(6):743-50.
Kristiansen MG, Løchen ML, Gutteberg TJ, Mortensen L, Eriksen BO, Florholmen J. Total and cause-specific mortality rates in a prospective study of community-acquired hepatitis C virus infection in northern Norway. Journal of viral hepatitis. 2011;18(4):237-44.
Lee MH, Yang HI, Wang CH, Jen CL, Yeh SH, Liu CJ, et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke. 2010;41(12):2894-900.
Liao CC, Su TC, Sung FC, Chou WH, Chen TL. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PloS one. 2012;7(2):e31527.
Alyan O, Kacmaz F, Ozdemir O, Deveci B, Astan R, Celebi AS, et al. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circulation journal: official journal of the Japanese Circulation Society.2008;72(12):1960-5.
Shakeri MT, Nomani H, Ghayour Mobarhan M, Sima HR, Gerayli S, Shahbazi S, et al. The Prevalence of Hepatitis C Virus in Mashhad, Iran: A Population-Based Study. Hepat Mon. 2013;13(3):e7723.
Mahmud S, Akbarzadeh V, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses. Scientific Reports. 2018;8(1):150.
- Abstract Viewed: 313 times
- PDF Downloaded: 181 times